OBJECTIVE: The aim of this study was to review the chemotherapy experience at Magee-Womens Hospital for malignant mixed müllerian tumor (MMMT) of the ovary. Patients were treated with either paclitaxel/carboplatin (PC) outpatient chemotherapy or platinum/ifosfamide (PI) inpatient chemotherapy as first- or second-line therapy. METHODS: Thirteen patients diagnosed with MMMT of the ovary after complete surgical staging from 1990 to 1999 were studied retrospectively. Six patients received PC combination chemotherapy, of which 3 patients received PC as first-line treatment. The other 3 patients received PC as second-line therapy. Eight patients were treated with PI. Demographic data, pathology, cytoreductive surgery, treatment, and survival rates were reviewed. Complete clinical response (CR) was defined as the disappearance of all measurable disease or normalization of elevated CA 125 level after chemotherapy. Kaplan-Meier analysis was used for survival analysis. RESULTS: The median survival time of patients receiving PC was 19 months. One patient, after receiving PC as first-line treatment, demonstrated a CR and is free of disease beyond 33 months. The median survival time of patients managed with PI was 23 months. Three patients with suboptimal disease demonstrated CR after receiving PI. CONCLUSIONS: Optimal chemotherapy regimen for MMMT of ovary remains to be determined. Platinum-based chemotherapy in combination with ifosfamide or paclitaxel may be active against this rare malignancy. Copyright 2000 Academic Press.
OBJECTIVE: The aim of this study was to review the chemotherapy experience at Magee-Womens Hospital for malignant mixed müllerian tumor (MMMT) of the ovary. Patients were treated with either paclitaxel/carboplatin (PC) outpatient chemotherapy or platinum/ifosfamide (PI) inpatient chemotherapy as first- or second-line therapy. METHODS: Thirteen patients diagnosed with MMMT of the ovary after complete surgical staging from 1990 to 1999 were studied retrospectively. Six patients received PC combination chemotherapy, of which 3 patients received PC as first-line treatment. The other 3 patients received PC as second-line therapy. Eight patients were treated with PI. Demographic data, pathology, cytoreductive surgery, treatment, and survival rates were reviewed. Complete clinical response (CR) was defined as the disappearance of all measurable disease or normalization of elevated CA 125 level after chemotherapy. Kaplan-Meier analysis was used for survival analysis. RESULTS: The median survival time of patients receiving PC was 19 months. One patient, after receiving PC as first-line treatment, demonstrated a CR and is free of disease beyond 33 months. The median survival time of patients managed with PI was 23 months. Three patients with suboptimal disease demonstrated CR after receiving PI. CONCLUSIONS: Optimal chemotherapy regimen for MMMT of ovary remains to be determined. Platinum-based chemotherapy in combination with ifosfamide or paclitaxel may be active against this rare malignancy. Copyright 2000 Academic Press.
Authors: C Kosmas; G Vorgias; G Tsakonas; P Politis; T Daladimos; E Panagiotidi; T Papachrysanthou; D Moschovis; N Kalinoglou; N Tsavaris; A Karabelis; N Mylonakis Journal: Br J Cancer Date: 2011-08-16 Impact factor: 7.640
Authors: Gretchen Glaser; S John Weroha; Marc A Becker; Xiaonan Hou; Sergio Enderica-Gonzalez; Sean C Harrington; Paul Haluska Journal: PLoS One Date: 2015-05-11 Impact factor: 3.240
Authors: Robert L Hollis; Ian Croy; Michael Churchman; Clare Bartos; Tzyvia Rye; Charlie Gourley; C Simon Herrington Journal: Br J Cancer Date: 2022-06-17 Impact factor: 9.075
Authors: Joshua D Bernstock; Stuart Ostby; Brandon Fox; Houman Sotoudeh; Andrew Janssen; Yun Jee Kang; Jason Chen; Veeranjaneyulu Prattipati; Galal Elsayed; Gustavo Chagoya; Daisuke Yamashita; Gregory K Friedman; Burt Nabors; Warner K Huh; Mina Lobbous Journal: Clin Case Rep Date: 2019-10-22